For investors
A dominant, global cannabis business.
Through owned and partnered production platforms — and education that helps customers use cannabis safely and responsibly — Canopy has built a global business with the potential to generate significant, sustained return on shareholder capital over the long term.
Q4 FY26 performance
Growth, branching out.
The core cannabis platform compounded on two fronts in the fourth quarter — steady gains at home and accelerating momentum abroad.
+27%
Q4 FY26 net revenue growth — Canada Medical
+68%
Q4 FY26 growth — International Markets Cannabis
Balance sheet
$131.3M
Net cash, fiscal year-end 2026 — a swing from net debt a year earlier.
Q4 growth by geography
Bars scaled for comparison · figures shown are actual Q4 FY26 growth
US$50B
Projected U.S. retail cannabis market in 2026 — the opportunity Canopy USA is built to reach.
Investor resources
Everything you need, in one place.
Earnings
Quarterly results, financial statements and investor presentations.
View →News Releases
The latest company announcements and press releases.
View →Investor FAQ
Answers to common questions about Canopy Growth shares.
View →Governance
Board of Directors and corporate governance leadership.
View →Analyst Coverage
Third-party analyst coverage of Canopy Growth.
View →Canopy USA
Our strategy to fast-track entry into the U.S. cannabis market.
View →Transfer agent
Canopy Growth's transfer agent is Computershare Investor Services Inc.
North America: 1 (800) 564-6253
International: 1 (514) 982-7555
Good to know
Shares of Canopy Growth cannot be purchased directly from the company. Market data is provided by QuoteMedia, and all analyst coverage is conducted by independent third parties.